Drug Trial Radar · NCT00269438
New Tablet Formulation and Dosing Regimen of Balsalazide Disodium in Mildly to Moderately Active Ulcerative Colitis
Last checked: Nov 20, 2026Latest source record: Nov 25, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
225
Actual
Start
Dec 2005
Primary completion
Mar 2007
Study completion Jun 2007
Sponsor
- Lead sponsor
- Bausch Health Americas, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 23, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Single group
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to establish the efficacy and safety of a new tablet formulation and dosing regimen of balsalazide disodium dosed twice daily in achieving clinical improvement in subjects with mildly to moderately active ulcerative colitis after 8 weeks of therapy.
Conditions
- Ulcerative Colitis
Interventions
5 ASA, enemas, suppositories, corticosteroidsDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of subjects that achieve clinical improvement and improvement in the rectal bleeding subscale of the MMDAI at the end of eight weeks of therapy, where clinical improvement is defined as a >3 point improvement from baseline in the MMDAI.
Locations
66 sites in 1 country. Site status is shown where the registry gives one.
Birmingham Gastroenterology Associates
Birmingham, Alabama
Spring Memorial Hospital
Mobile, Alabama
Little Rock Diagnostic Clinic
Little Rock, Arkansas
Advanced Clinical Research Institute
Anaheim, California
Lovelace Scientific Resources
Beverly Hills, California
Digestive Liver Disease Specialists, Medical Group
Garden Grove, California
Therapeutic Research Institute of Orange County
Laguna Hills, California
Long Beach VA Medical Center
Long Beach, California
Facey Medical Group
Mission Hills, California
Community Clinical Trials
Orange, California
Rider Research Group
San Francisco, California
John Jolley, M.D.
San Rafael, California
Lovelace Scientific Resources
Santa Ana, California
Santa Barbara Clinical Research
Santa Barbara, California
Connecticut Gastroenterology Institute
Bristol, Connecticut
Stamford Therapeutic Consortium
Stamford, Connecticut
Medical Research Unlimited
Hialeah, Florida
Mark Lamet, M.D.
Hollywood, Florida
Southern Clinical Research Consultants
Hollywood, Florida
United Medical Research
New Smyrna Beach, Florida
Venture Research Institute, LLC
North Miami Beach, Florida
Advanced Gastroenterology Associates
Palm Harbor, Florida
Lovelace Scientific Resources
Sarasota, Florida
Advent Clinical Research
Sarasota, Florida
Clinical Research of Tampa Bay, Inc.
Spring Hill, Florida
Metabolic Research Institute, Inc.
West Palm Beach, Florida
Gary Richter, M.D.
Atlanta, Georgia
The Atlanta Center for Gastroenterology
Decatur, Georgia
Gastroenterology Associates of Central Georgia
Macon, Georgia
Northwest Gastroenterologists S.C.
Arlington Heights, Illinois
University Digestive Health Center
Oak Forest, Illinois
Covenent Clinic
Waterloo, Iowa
Digestive Health Center
Topeka, Kansas
University of Louisville
Louisville, Kentucky
Digestive Health Center of Louisiana
Baton Rouge, Louisiana
Woodholme Gastroenterology Associates, PA
Baltimore, Maryland
Sinai Medical Office Building
Baltimore, Maryland
Mid Atlantic Medical Research Centers
Hollywood, Maryland
Clinical Research Institute of Michigan, LLC
Chesterfield, Michigan
Site not named
Kansas City, Missouri
Showing 40 of 66 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.